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Abstract
Purpose Obstructive sleep apnea (OSA) is a common condition characterized by repetitive collapse of the upper airways 
and intermittent oxygen desaturation, which may lead to airway inflammation. Here, we explored whether fractional exhaled 
nitric oxide (FeNO) levels provide a non-invasive screening tool of OSA.
Methods Over a 3-month period, FeNO levels were measured in consecutive non-smoking patients referred for a sleep 
laboratory. All patients underwent full polysomnography. OSA severity was classified based on the apnea/hypopnea index: 
≥ 5.0/h as any OSA, ≥ 15.0/h as moderate/severe OSA, and ≥ 30.0/h as severe OSA. FeNO was measured by a portable device 
(NIOX-MINO®; Aerocrine AB, Solna, Sweden) and expressed as parts per billion (ppb). Discrimination by area under the 
curve (AUC) and binary logistic regression were performed.
Results A total of 229 subjects were evaluated. Mean FeNO values were similar among subjects without OSA or with OSA: 
16.9 ± 10.6 ppb versus 20.2 ± 14.5 ppb, p = 0.221; respectively. FeNO was not an inclusionary parameter to predict any OSA, 
moderate/severe OSA, and severe OSA: odds ratio (OR) 1.023 (95% confidence interval [CI]: 0.986–1.062); OR 1.012 (95% 
CI: 0.991–1.034); and OR 0.999 (95% CI: 0.980–1.018), respectively. The AUC values for FeNO in the diagnosis of any 
OSA, moderate/severe OSA, and severe OSA showed no discriminatory properties: AUC: 0.567 (95% CI: 0.464–0.670), 
AUC: 0.541 (95% CI: 0.465–0.618), and AUC: 0.535 (95% CI: 0.459–0.610); respectively.
Conclusions In a sleep-lab setting, our findings suggest that FeNO measurements are inconsequential in the screening of 
OSA in adults.
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Introduction
Obstructive sleep apnea (OSA) is a highly prevalent disor-
der characterized by recurrent upper airway obstructive epi-
sodes, resulting in intermittent hypoxemia and arousals. The 
estimated prevalence of moderate-to-severe sleep-disordered 
breathing (SDB) ranges from 10 to 17% among men and 
from 3 to 9% among women [1], likely reflecting the increase 
in obesity rates and aging of the population [2, 3]. In certain 
risk groups, such as patients undergoing pre-operative evalu-
ation for bariatric surgery [4] or resistant hypertension [5], 
the prevalence can reach more than 70%. In patients with 
OSA, the recurrent snoring and associated local mechanical 
trauma to the airway along with the recurrent upper airway 
collapse and intermittent hypoxia-re-oxygenation episodes 
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lead to release of inflammatory mediators, leading to both 
local upper airway and systemic inflammation [6].
Fractional exhaled nitric oxide (FeNO) can be easily, rap-
idly, and non-invasively measured for assessment of airway 
inflammation, and is extensively used in asthma to evalu-
ate both severity and therapeutic responses [7–9]. However, 
FeNO levels in OSA patients remain somewhat unclear [10]: 
both elevated FeNO [11–15] and unaltered FeNO levels 
[16–19] have been reported when comparing OSA patients 
to controls. A recent meta-analysis [10] addressed FeNO lev-
els in patients with OSA and concluded that there was a sig-
nificant increase in FeNO levels in subjects diagnosed with 
OSA. Moreover, FeNO levels were significantly increased 
upon waking up in patients with OSA, but such pattern 
was not present in non-OSA groups. In addition, long-term 
continuous positive airway pressure (CPAP) significantly 
lowered FeNO levels in OSA patients. Notwithstanding the 
conclusions of the meta-analysis, some limitations are wor-
thy of mention: (i) the available literature contains studies 
with a relatively small sample size; (ii) different techniques 
and instruments were used for FeNO measurements; (iii) 
substantial heterogeneity was present across the cohorts that 
were evaluated; and (iv) insufficient information regarding 
confounding factors, such as snoring or timing of FeNO 
measurement [10].
Here, we hypothesized that FeNO value is useful in the 
screening of OSA. Our major objectives in the context of 
FeNO measurements were (i) to verify if FeNO levels dis-
criminate between patients with and without OSA and (ii) 
to evaluate whether FeNO levels can be used as a screening 
tool in patients with suspected OSA.
Methods
This cross-sectional study evaluated consecutive patients 
enrolled between January 2017 and March 2017, who were 
referred by their respective attending physicians. All studies 
were conducted in a single Brazilian center: Sleep Labora-
tory at Centro Medico BarraShopping, Rio de Janeiro. Inclu-
sion criteria were subjects of both genders, aged ≥ 18 years 
with suspected SDB. Patients were excluded for any of the 
following reasons: current smokers, inhaled and/or systemic 
corticosteroids use, self-reported information of atopy or 
respiratory disease that might affect FeNO measurements 
(allergic rhinitis, asthma, and chronic obstructive pulmo-
nary disease [COPD]), current respiratory tract infection, 
previously diagnosed OSA, and insufficient sleep or techni-
cally inadequate polysomnography (PSG). The study was 
approved by the Ethics Committee of the Federal Univer-
sity of Rio de Janeiro, Brazil (#1.764.165) and it was devel-
oped in accordance with the ethical standards laid down in 
the Declaration of Helsinki. All participants gave written 
informed consent prior any study procedure.
Patient characteristics included gender, race, age, body 
mass index (BMI), neck circumference (NC), and self-
reported comorbidities (diabetes mellitus and hypertension). 
Patients were measured for weight and height, and BMI was 
calculated by dividing the weight in kilograms by the square 
of the height in meters (kg/m2), while NC was systemati-
cally measured, in centimeters, with a tape measure. All 
patients enrolled had complete data regarding the filling of 
two validated models: the Epworth Sleepiness Scale (ESS) 
[20] and the No-Apnea [21]. The ESS [20] is a questionnaire 
with eight questions related to the chance of dozing in daily 
situations, being its final score ranging from 0 to 24 points. 
Individuals with scores > 10 points are classified as having 
excessive daytime sleepiness [20]. The No-Apnea [21] is a 
newly developed and validated model, consisting of only two 
objective and easily measurable parameters: NC scored from 
0 to 6 points and age scored from 0 to 3 points (final score 
ranging from 0 to 9 points). Subjects with scores ≥ 3 points 
are classified as high risk for OSA diagnosis [21].
FeNO Measurements
The measurements of FeNO were performed according to 
the recommendations proposed by the American Thoracic 
Society [7], always in the morning and immediately after 
the PSG, under the direction of an experienced technician. 
FeNO was measured by a portable device (NIOX-MINO®; 
Aerocrine AB, Solna, Sweden) and expressed as parts per 
billion (ppb). They were seated without a nose clip, inhaled 
to total lung capacity, and then exhaled at a constant flow 
rate of 50 mL/s as guided by an eye-level indicator for 
approximately 10 s. Two successive FeNO measurements 
were obtained and their mean values were recorded for 
analysis.
Sleep Test
All patients underwent an attended, in-laboratory PSG 
(EMBLA® S7000, Embla Systems, Inc., Broomfield, CO, 
USA), consisting of continuous monitoring of electroen-
cephalography, electrooculography, electromyography (chin 
and legs), electrocardiography, oronasal airflow, thoracic 
and abdominal belts, pulse oximetry to measure oxygen 
saturation  (SpO2), snoring microphone, and body position 
sensor. The scoring was performed manually and was inter-
preted by two board-certified sleep physicians in accordance 
with previous guidelines [22], being that both physicians 
were blinded to the FeNO values. Data from PSG included 
total sleep time, sleep efficiency, sleep stages, rapid eye 
movement and sleep latencies, arousal index, apnea/hypo-
pnea index (AHI),  SpO2 values (awake, mean, nadir, and 
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cumulative time with  SpO2 < 90%), and oxygen desaturation 
index (ODI) with a threshold of 3%. Apneas were classified 
with a drop ≥ 90% of baseline in airflow lasting at least 10 s 
[22]. Hypopneas were classified with a drop ≥ 30% of pre-
event during ≥ 10 s associated with ≥ 3% oxygen desatura-
tion or an arousal [22]. Diagnosis of OSA was based on an 
AHI ≥ 5.0/h, being its severity classified based on the AHI 
thresholds: ≥ 5.0/h as any OSA, ≥ 15.0/h as moderate/severe 
OSA, and ≥ 30.0/h as severe OSA.
Statistical Analysis
Data analysis was conducted using a statistical software 
package (SPSS, version 21.0; Chicago, IL, USA). Results 
are presented as mean ± standard deviation for continuous 
variables and as number and percentage for categorical vari-
ables. Comparisons between groups were performed using 
the Chi-square test for dichotomous variables, Student’s t 
test, and univariate analysis of variance (ANOVA) for con-
tinuous variables. Correlation was evaluated by Spearman 
rank correlation coefficient (r). At three AHI thresholds 
(5.0/h, 15.0/h, and 30.0/h), the predictive performance of 
FeNO was assessed by logistic regression tests and receiver 
operating characteristic (ROC) curves with area under the 
curve (AUC). An AUC > 0.7 was considered as clinically 
significant discrimination. Both AUC and odds ratio (OR) 
were reported with their respective 95% confidence intervals 
(CI).
Results
Of a total of 272 consecutive subjects referred for diagnos-
tic PSG, 43 patients (15.8%) were subsequently excluded: 
31 patients were using corticosteroids and/or had known 
respiratory disease and 12 patients were current smokers. 
Thus, a total of 229 adult patients—including 162 males 
(70.7%) and 67 females (29.3%)—were considered eligi-
ble for further analyses. No PSG needed to be repeated. 
Baseline and polysomnographic characteristics are shown 
in Table 1. Mean age was 43.7 ± 12.6 years, mean BMI was 
31.1 ± 6.5 kg/m2, and mean NC was 40.6 ± 4.5 cm. Hyper-
tension and diabetes mellitus were present in 32.8% and 
14.0% of the patients, respectively. As anticipated from the 
study design and recruitment of a referral cohort to a sleep-
laboratory setting, we found a high frequency of any OSA 
(86.9%), moderate/severe OSA (62.4%), and severe OSA 
(39.7%). As expected, patients with diagnosis of any OSA, 
moderate/severe OSA, and severe OSA had a male predomi-
nance (73.9%, 76.2%, and 83.5%; respectively). There were 
no gender differences in FeNO values: 18.1 ± 14.1 ppb in 
females versus 20.5 ± 14.0 ppb in males; p = 0.234.
Mean ESS was 9.4 ± 4.5 points, being that 38.9% of the 
patients were sleepy. We observed a poor discrimination 
of ESS in predicting any OSA, moderate/severe OSA, and 
severe OSA: AUC: 0.537 (95% CI: 0.405–0.669; p = 0.517), 
AUC: 0.529 (95% CI: 0.451–0.606; p = 0.466), and AUC: 
0.565 (95% CI: 0.490–0.640; p = 0.097); respectively. Con-
versely, No-Apnea model showed to be a useful tool for 
screening of any OSA, moderate/severe OSA and severe 
OSA: AUC: 0.786 (95% CI: 0.696–0.877; p < 0.001), AUC: 
0.713 (95% CI: 0.644–0.782; p < 0.001), and AUC: 0.717 
(95% CI: 0.650–0.784; p < 0.001); respectively.
Correlation
Table 2 shows the correlation between FeNO and some 
numeric parameters: all clinical and polysomnographic 
Table 1  Patients characteristics (n = 229)
Numeric and categorical variables were presented as mean ± standard 
deviation and n (%), respectively
BMI body mass index, NC neck circumference, ESS Epworth Sleepi-
ness Scale, FeNO fraction of exhaled nitric oxide, AHI Apnea/Hypo-
pnea Index, REM rapid eye movement, SpO2 oxygen saturation, ODI 
oxygen desaturation index at 3%
Parameter Values
Clinical data
 Male gender (%) 162 (70.7)
 Age (years) 43.7 ± 12.6
 BMI (kg/m2) 31.1 ± 6.5
 NC (cm) 40.6 ± 4.5
 Caucasian (%) 185 (80.8)
 Hypertension (%) 75 (32.8)
 Diabetes mellitus (%) 32 (14.0)
 ESS, points 9.4 ± 4.5
 No-Apnea, points 4.4 ± 2.5
FeNO (ppb) 19.8 ± 14.1
Polysomnographic data
 Total sleep time (min) 339.3 ± 58.8
 Sleep efficiency (%) 79.7 ± 13.2
 Sleep latency (min) 39.1 ± 39.0
 REM latency (min) 140.5 ± 71.1
 Sleep stage NREM1 (%) 6.4 ± 5.0
 Sleep stage NREM2 (%) 66.2 ± 10.4
 Sleep stage NREM3 (%) 9.5 ± 8.1
 Sleep stage REM (%) 17.5 ± 6.8
 Arousal index (n/h) 31.0 ± 25.3
 AHI (n/h) 30.1 ± 26.7
 Awake  SpO2 (%) 94.6 ± 1.7
 Mean  SpO2 (%) 92.8 ± 2.9
 Nadir  SpO2 (%) 82.0 ± 8.8
 ODI (n/h) 26.9 ± 25.9
 SpO2 < 90% (min) 27.0 ± 51.3
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data evaluated failed to reveal any significant correlation 
with FeNO values, except for age (r = 0.134; p = 0.042), 
No-Apnea model (r = 0.156; p = 0.018), and awake  SpO2 
(r = − 0.148; p = 0.025); however, all of them show a weak 
correlation. As shown in Table 2, the correlation between 
FeNO and parameters related with OSA severity (AHI, nadir 
 SpO2, ODI at 3%, and cumulative time with  SpO2 < 90%) 
were all not significant: r = 0.068 with p = 0.304; r = − 0.082 
with p = 0.218; r = 0.099 with p = 0.161; and r = 0.050 with 
p = 0.481, respectively (Fig. 1).
Predicting OSA with FeNO
Mean FeNO values were similar among subjects with-
out OSA (AHI < 5.0/h) or with OSA (AHI ≥ 5.0/h): 
16.9 ± 10.6 ppb versus 20.2 ± 14.5 ppb, p = 0.221; respec-
tively. In addition, Fig.  2 shows FeNO measurements 
according to four AHI intervals: < 5.0/h (without OSA), 
5.0–14.9/h (mild OSA), 15.0–29.9/h (moderate OSA), and 
≥ 30.0/h (severe OSA), illustrating that mean FeNO values 
were not statistically different across severity categories 
based on AHI (p value for trend = 0.392).
FeNO was not a relevant retainable parameter to pre-
dict any OSA, moderate/severe OSA, and severe OSA: 
OR 1.023 (95% CI: 0.986–1.062; p = 0.220); OR 1.012 
(95% CI: 0.991–1.034; p = 0.251); and OR 0.999 (95% 
CI: 0.980–1.018; p = 0.931), respectively. Corroborat-
ing the findings described above, we also observed a poor 
discrimination of FeNO in predicting any OSA, moderate/
severe OSA, and severe OSA (Fig. 3): AUC: 0.567 (95% CI: 
0.464–0.670; p = 0.235), AUC: 0.541 (95% CI: 0.465–0.618; 
p = 0.295), and AUC: 0.535 (95% CI: 0.459–0.610; 
p = 0.376), respectively.
Discussion
In the present study, FeNO measurements emerge as a 
clearly not useful measurement when applied as a potential 
screening tool for OSA in patients with a high pre-test prob-
ability of SDB. In addition, our study indicated that FeNO 
values were not significantly different in those patients with 
or without OSA. Studies investigating the effect of OSA on 
FeNO measurements are inconsistent and with conflicting 
results [10–19, 23]. Similar to our findings, a study [19] 
with 129 consecutive patients, aged ≥ 16 years, showed no 
value in incorporating FeNO in the screening of OSA, con-
sidering that FeNO values were similar among individuals 
with or without SDB, and also whether SDB was defined 
by an AHI threshold of ≥ 5.0/h or ≥ 15.0/h. Similarly, there 
were no differences in FeNO concentrations in individuals 
with OSA (n = 24) and in healthy individuals (n = 7) [18]. A 
probable explanation for current findings could be that the 
inflammation that is generally present in patients with OSA 
may not be eosinophilic in nature. In addition, exclusion of 
patients with allergic rhinitis, asthma, and asthma–COPD 
overlap may also have contributed to the negative findings 
of FeNO as a screening approach for OSA.
Our study was conducted with FeNO measurements being 
always performed in the morning, aiming to minimize pos-
sible circadian-related variations, a feature that has been pre-
viously reported as a potential confounder [24]. Differences 
before and after the sleep periods [16] have led to the rec-
ommendation of standardizing the time of day when FeNO 
measurements are conducted. Moreover, it was also noted 
that establishment of reference values for FeNO is difficult, 
given the large number of frequently occurring factors that 
can influence this measurement [25]. For example, smoking, 
gender, age, weight, height, atopy, respiratory/nasal symp-
toms, use of steroids, and diet have all been implicated in 
the variance of FeNO.
A previous study [17] evaluated the changes of FeNO 
before and after sleep as function of BMI. FeNO levels 
in subjects without OSA as well as those with OSA were 
similar, but significant increases were detected in obese 
patients with OSA, suggesting that obesity is modifying 
factor and potentially enhances inflammation in the airways 
in patients with OSA [17]. Similarly, a study [11] with 43 
individuals (18 obese patients with OSA, 15 obese patients 
without OSA, and 10 healthy subjects) showed that FeNO 
was significantly increased in OSA and in obese patients 
Table 2  Correlation between FeNO values and other measures 
(n = 229)
The FeNO values were correlated with age, No-Apnea model, and 
awake  SpO2; however, all of them reporting a weak correlation
BMI body mass index, NC neck circumference, ESS Epworth Sleepi-
ness Scale, AHI Apnea/Hypopnea Index, SpO2 oxygen saturation, 






 Age (years) 0.134 0.042
 BMI (kg/m2) 0.048 0.468
 NC (cm) 0.121 0.067
 ESS score, points 0.051 0.440
 No-Apnea, points 0.156 0.018
Polysomnographic data
 AHI (n/h) 0.068 0.304
 Awake  SpO2 (%) − 0.148 0.025
 Mean  SpO2 (%) − 0.027 0.687
 Nadir  SpO2 (%) − 0.082 0.218
 ODI (n/h) 0.099 0.161
 SpO2 < 90% (min) 0.050 0.481
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(23.1 ± 2.1 ppb and 17.9 ± 2.1 ppb) when compared to con-
trols (7.2 ± 0.6 ppb), thereby supporting the hypothesis 
that obesity alone can alter the inflammatory status of the 
upper airway. Concurring findings [14] were reported in 60 
patients reinforcing the concept that inflammation of the 
upper airways in obese patients with OSA and without OSA 
may be monitored by FeNO measurements.
Interestingly, in a series of 104 consecutive adult non-
smokers (75 patients with OSA and 29 controls), FeNO val-
ues were elevated in OSA, were correlated with severity, and 
decreased after positive pressure therapy [12]. Furthermore, 
in patients with OSA, FeNO levels were significantly higher 
after sleep compared to measurements conducted at bed-
time (19.0 ± 7.7 ppb vs. 13.4 ± 6.5 ppb), while there were 
no significant overnight changes in patients without OSA. 
In addition, FeNO levels declined after 1–3 months of CPAP 
Fig. 1  Scatterplot of individual AHI values, nadir oxygen saturation 
 (SpO2), ODI at 3%, and cumulative time with  SpO2 < 90% plotted 
against the corresponding FeNO concentrations in 229 subjects. The 
Spearman rank correlation coefficients between FeNO and AHI, nadir 
 SpO2, ODI at 3%, and cumulative time with  SpO2 < 90% were all not 






















Fig. 2  FeNO concentrations according to four AHI intervals: < 5.0/h 
(without OSA), 5.0–14.9/h (mild OSA), 15.0–29.9/h (moderate 
OSA), and ≥ 30.0/h (severe OSA). Values of FeNO were reported as 
mean ± standard deviation. The mean FeNO values were not statisti-
cally different across categories de AHI (p value for trend = 0.392)
136 Lung (2019) 197:131–137
1 3
therapy (11.7 ± 4.4 ppb, p < 0.001). Nearly identical results 
were reported in a smaller series of 26 patients [26]. Thus, 
based on aforementioned studies, it would appear that CPAP 
therapy yields clinical benefits by reducing upper airway 
inflammation and oxidative stress in OSA patients.
Similar to our findings, some studies have shown no 
usefulness of ESS as a screening tool for OSA [27–30]. 
Conversely, a practical and extremely simple 2-item model, 
No-Apnea [21], showed adequate discriminatory ability for 
detection of OSA in a clinical referral cohort. In the origi-
nal derivation cohort, the AUCs for screening for any OSA, 
moderate/severe OSA, and severe OSA were: 0.784 (95% CI: 
0.761–0.808); 0.758 (95% CI: 0.737–0.777), and 0.754 (95% 
CI: 0.733–0.776); respectively, and the validation cohort 
essentially confirmed such findings, thereby establishing its 
reproducibility, and its non-inferiority performance when 
compared to two previously validated tools (STOP-Bang 
questionnaire [31] and NoSAS score [32], containing eight 
and five parameters, respectively) [21].
Limitations and Strengths
Our study had some limitations: patient selection occurred in 
a single sleep laboratory; therefore the possibility of selec-
tion bias is plausible and generalizability of the findings may 
be limited. In most sleep laboratories, patients referred for 
PSG are often suspected of suffering from OSA and there-
fore represent a high pre-test probability cohort. In addi-
tion, all patients included had FeNO measured at the same 
time (only in the morning): this certainly does not exclude 
daily variations, it only minimizes circadian or time of day 
confounders as possible measurement bias. According to 
some previous studies [12, 13, 17], which have shown that 
FeNO measurements are greater immediately upon awak-
ening than at night, especially in patients with OSA ver-
sus patients without OSA, we chose to measure FeNO in 
the next morning after PSG, immediately upon waking up. 
However, several points are also worthy of mention. Our 
patients were consecutively and prospectively recruited and 
the sample size was larger than other similar studies that 
have previously evaluated FeNO. All patients underwent 
in-lab PSG with the same diagnostic criteria proposed by 
American Academy of Sleep Medicine [22], regardless of 
whether their clinical symptoms included respiratory com-
plaints or not. Moreover, all polysomnographic studies were 
of sufficient quality for inclusion in the analyses.
Conclusions
In a contextual setting of clinical referral cohort to a sleep 
laboratory, FeNO measurements do not show evidence of 
sufficient discriminatory ability to warrant the inclusion of 
this measurement for the screening of OSA in adult patients.
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